Vicarious Surgical Inc

Vicarious Surgical, Inc. engages in advancing the field of surgical robotics. Through the use of surgical robotics, the company aims to improve patients lives, surgeons abilities, and expand global access to high-quality care. The company was founded by Adam Sachs and Sammy Khalifa on May 6, 2020 and is headquartered in Waltham, MA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Vicarious Surgical reports Q2 loss, eyes FDA milestones for growth

Vicarious Surgical's Q2 performance reflects a focus on innovation, regulatory compliance, and strategic leadership.
The company's strong cash position, upcoming milestones, and product development efforts signal growth potential.
Challenges in managing expenses, regulatory hurdles, and market competition require careful navigation and strategic planning.
Opportunities lie in expanding partnerships, FDA approvals, and leveraging the demand for minimally invasive surgical solutions.

Vicarious Surgical reports improved finances but faces delays in flagship program

Vicarious Surgical navigated challenges with financial improvements but faces delays in their flagship program. Despite setbacks, the company remains committed to revolutionizing robotic surgery and enhancing capital efficiency.

Vicarious Surgical reports progress in product development and funding

Vicarious Surgical navigated challenges in 2023, strengthened its product offering, and secured funding for future growth. The company's financial position is stable, with a focus on achieving milestones in 2024. Leveraging partnerships and regulatory clarity present growth opportunities.

Vicarious Surgical reports strong Q1 performance and eyes global expansion

Vicarious Surgical's Q1 2024 performance reflects financial improvements and technological advancements, positioning the company for future growth.
While facing challenges in system integration and regulatory processes, the company's strengths in technology innovation and leadership provide a strong foundation for success.
Opportunities in international expansion, strategic partnerships, and regulatory advancements present avenues for Vicarious Surgical to capitalize on its unique market position and drive long-term value.

Vicarious Surgical reports Q2 progress amidst financial challenges

Vicarious Surgical's Q2 2024 performance showed progress in system integration and partnerships, but also highlighted financial challenges.
The company's strong cash position and focus on upcoming milestones position it well for future growth opportunities.
Analyst questions underscore the need for Vicarious Surgical to address financial concerns and execute on its strategic initiatives effectively.

Vicarious Surgical reports improved financials and progresses on robotic platform

Vicarious Surgical's Q3 2024 performance showed financial improvements and progress in developing its single-port platform for robotic surgery. While challenges and uncertainties exist, the company's focus on cost management and regulatory readiness bode well for future growth and innovation.

Vicarious Surgical reports progress in technology and partnerships amid financial challenges

Vicarious Surgical showcased technological advancements and strategic partnerships in Q4 2024, despite facing financial challenges and supply chain issues. The company's focus on innovation, operational efficiency, and financial management will be critical for future growth and sustainability. With a strong cash position and plans for strategic balance sheet reinforcement, Vicarious Surgical is poised to navigate challenges and capitalize on opportunities. Investors should monitor the company's progress in driving adoption of the V1.0 system and managing costs effectively for sustainable growth.

Vicarious Surgical reports Q1 progress, confident in funding and partnerships

Vicarious Surgical's Q1 2025 performance reflects progress in key milestones, disciplined spending, and strategic financing options. The company's strengths lie in its confidence in funding operations, positive supply chain outlook, and focus on hospital partnerships. Challenges include managing cash burn, ensuring timely technical dossier filing, and ongoing supply chain management. Opportunities for Vicarious Surgical include driving adoption through partnerships, leveraging strategic alliances, and successful product development.

Vicarious Surgical delays trials to focus on tech development and milestones

Vicarious Surgical prioritized technology development over clinical trials in Q2 2025, reporting financials and expressing confidence in the team and technology. Challenges include delays in trials, budget implications, and timeline shifts, requiring thorough system assessment. Opportunities for growth exist in completing the production system and advancing minimally-invasive surgery technology.

Vicarious Surgical cuts costs and boosts system performance in Q3

Vicarious Surgical made significant progress in cost reduction and product performance enhancements in Q3 2025. The company's strategic focus on achieving design freeze and engaging with partners reflects a commitment to innovation. Challenges in managing expenses and controlling burn underscore the importance of efficient operations and financial discipline. Opportunities for growth and market differentiation exist through optimizing outsourcing, enhancing system performance, and fostering partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vicarious Surgical, Inc. a blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It also designs surgical robotics. The company was founded by Adam Sachs, Sammy Khalifa, and Barry Greene on May 1, 2014 and is headquartered in Waltham, MA.